Literature DB >> 24493853

Preliminary study of autologous bone marrow nucleated cells transplantation in children with spinal cord injury.

Danuta Jarocha1, Olga Milczarek, Zdzislaw Kawecki, Anna Wendrychowicz, Stanislaw Kwiatkowski, Marcin Majka.   

Abstract

The objective of this study was to assess the safety and efficacy of transplanting bone marrow nucleated cells (BMNCs) to treat children with complete interruption of spinal cord (SC) continuity. The present study was conducted from 2005 to 2011. The inclusion criteria were a magnetic resonance imaging-confirmed complete interruption of SC continuity and no improvement in neurological status within 6 months after standard therapy. Bone marrow was isolated from the iliac ala and submitted to BMNC isolation. Subsequently, the cell suspension was administered into the SC cavity and intravenously. In total, 18 of 19 intraspinal and intravenous BMNC transplantation procedures performed caused no adverse events. One case was connected with transient bradycardia. The experimental therapy showed no late complications in the 1- to 6-year follow-up evaluation period. Neurological improvement was observed in two patients who received multiple implantations. One patient demonstrated improved superficial sensation from Th3 to Th12/L1 and a restored bladder-filling sensation. In the other case, superficial sensation was improved from C2 to C5, and the respiratory drive, the swallowing reflex, and tongue movements were restored. Spasticity and quality of life were improved in three of five patients. In addition, skin pressure ulcers healed and did not recur. Our preliminary results demonstrate the safety and feasibility of BMNC transplantation in children with complete SC injury. The results indicate that a certain degree of neurological and quality-of-life improvement can be attained by children with chronic complete SC injury who receive multiple BMNC implantations.

Entities:  

Keywords:  Cell therapy; Cell transplantation; Spinal cord injury; Tissue regeneration; Transplantation

Mesh:

Year:  2014        PMID: 24493853      PMCID: PMC3952933          DOI: 10.5966/sctm.2013-0141

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  56 in total

1.  Regeneration of sensory axons within the injured spinal cord induced by intraganglionic cAMP elevation.

Authors:  Simona Neumann; Frank Bradke; Marc Tessier-Lavigne; Allan I Basbaum
Journal:  Neuron       Date:  2002-06-13       Impact factor: 17.173

2.  Remyelination of the spinal cord following intravenous delivery of bone marrow cells.

Authors:  Yukinori Akiyama; Christine Radtke; Osamu Honmou; Jeffery D Kocsis
Journal:  Glia       Date:  2002-09       Impact factor: 7.452

3.  Anti-Nogo-A antibody treatment enhances sprouting of corticospinal axons rostral to a unilateral cervical spinal cord lesion in adult macaque monkey.

Authors:  Patrick Freund; Thierry Wannier; Eric Schmidlin; Jocelyne Bloch; Anis Mir; Martin E Schwab; Eric M Rouiller
Journal:  J Comp Neurol       Date:  2007-06-01       Impact factor: 3.215

4.  Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: A phase I/II clinical safety and primary efficacy data.

Authors:  Arachimani Anand Kumar; Sankaran Raj Kumar; Raghavachary Narayanan; Kanagarajan Arul; Mayakesavan Baskaran
Journal:  Exp Clin Transplant       Date:  2009-12       Impact factor: 0.945

Review 5.  Mesenchymal stem cells: characteristics and clinical applications.

Authors:  Sylwia Bobis; Danuta Jarocha; Marcin Majka
Journal:  Folia Histochem Cytobiol       Date:  2006       Impact factor: 1.698

6.  A 37-year-old spinal cord-injured female patient, transplanted of multipotent stem cells from human UC blood, with improved sensory perception and mobility, both functionally and morphologically: a case study.

Authors:  K-S Kang; S W Kim; Y H Oh; J W Yu; K-Y Kim; H K Park; C-H Song; H Han
Journal:  Cytotherapy       Date:  2005       Impact factor: 5.414

7.  Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes.

Authors:  Pingping Huang; Shangzhu Li; Mingzhe Han; Zhijian Xiao; Renchi Yang; Zhong Chao Han
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

8.  Combinatorial therapy with neurotrophins and cAMP promotes axonal regeneration beyond sites of spinal cord injury.

Authors:  Paul Lu; Hong Yang; Leonard L Jones; Marie T Filbin; Mark H Tuszynski
Journal:  J Neurosci       Date:  2004-07-14       Impact factor: 6.167

9.  IGF-I gene delivery promotes corticospinal neuronal survival but not regeneration after adult CNS injury.

Authors:  Edmund R Hollis; Paul Lu; Armin Blesch; Mark H Tuszynski
Journal:  Exp Neurol       Date:  2008-10-02       Impact factor: 5.330

10.  Safety and possible outcome assessment of autologous Schwann cell and bone marrow mesenchymal stromal cell co-transplantation for treatment of patients with chronic spinal cord injury.

Authors:  Saeed Oraee Yazdani; Maryam Hafizi; Ali-Reza Zali; Amir Atashi; Farzad Ashrafi; Amir-Saeed Seddighi; Masoud Soleimani
Journal:  Cytotherapy       Date:  2013-07       Impact factor: 5.414

View more
  12 in total

1.  Clinical Study of NeuroRegen Scaffold Combined With Human Mesenchymal Stem Cells for the Repair of Chronic Complete Spinal Cord Injury.

Authors:  Yannan Zhao; Fengwu Tang; Zhifeng Xiao; Guang Han; Nuo Wang; Na Yin; Bing Chen; Xianfeng Jiang; Chen Yun; Wanjun Han; Changyu Zhao; Shixiang Cheng; Sai Zhang; Jianwu Dai
Journal:  Cell Transplant       Date:  2017-02-09       Impact factor: 4.064

2.  Defining recovery neurobiology of injured spinal cord by synthetic matrix-assisted hMSC implantation.

Authors:  Alexander E Ropper; Devang K Thakor; InBo Han; Dou Yu; Xiang Zeng; Jamie E Anderson; Zaid Aljuboori; Soo-Woo Kim; Hongjun Wang; Richard L Sidman; Ross D Zafonte; Yang D Teng
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

Review 3.  Harnessing the power of cell transplantation to target respiratory dysfunction following spinal cord injury.

Authors:  Brittany A Charsar; Mark W Urban; Angelo C Lepore
Journal:  Exp Neurol       Date:  2016-08-13       Impact factor: 5.330

4.  Autologous bone marrow cell transplantation in acute spinal cord injury--an Indian pilot study.

Authors:  H S Chhabra; K Sarda; M Arora; R Sharawat; V Singh; A Nanda; G M Sangodimath; V Tandon
Journal:  Spinal Cord       Date:  2015-08-18       Impact factor: 2.772

Review 5.  Potential for Stem Cells Therapy in Alzheimer's Disease: Do Neurotrophic Factors Play Critical Role?

Authors:  Parul Bali; Debomoy K Lahiri; Avijit Banik; Bimla Nehru; Akshay Anand
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

Review 6.  Concise Review: Bridging the Gap: Novel Neuroregenerative and Neuroprotective Strategies in Spinal Cord Injury.

Authors:  Christopher S Ahuja; Michael Fehlings
Journal:  Stem Cells Transl Med       Date:  2016-04-29       Impact factor: 6.940

7.  Stem cell therapy in spinal trauma: Does it have scientific validity?

Authors:  Harvinder Singh Chhabra; Kanchan Sarda
Journal:  Indian J Orthop       Date:  2015 Jan-Feb       Impact factor: 1.251

Review 8.  Recent advances in managing a spinal cord injury secondary to trauma.

Authors:  Christopher S Ahuja; Allan R Martin; Michael Fehlings
Journal:  F1000Res       Date:  2016-05-27

9.  Multiple Autologous Bone Marrow-Derived CD271+ Mesenchymal Stem Cell Transplantation Overcomes Drug-Resistant Epilepsy in Children.

Authors:  Olga Milczarek; Danuta Jarocha; Anna Starowicz-Filip; Stanislaw Kwiatkowski; Bogna Badyra; Marcin Majka
Journal:  Stem Cells Transl Med       Date:  2017-12-10       Impact factor: 6.940

10.  Human bone marrow-derived and umbilical cord-derived mesenchymal stem cells for alleviating neuropathic pain in a spinal cord injury model.

Authors:  Mahmoud Yousefifard; Farinaz Nasirinezhad; Homa Shardi Manaheji; Atousa Janzadeh; Mostafa Hosseini; Mansoor Keshavarz
Journal:  Stem Cell Res Ther       Date:  2016-03-08       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.